Sign In  |  Register  |  About San Rafael  |  Contact Us

San Rafael, CA
September 01, 2020 1:37pm
7-Day Forecast | Traffic

  • Search Hotels in San Rafael

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axsome Thera (NQ: AXSM )

88.84 -0.19 (-0.21%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axsome Thera

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
What's Going On Neurology-Focused Axsome Therapeutics' Stock On Monday?
Unlock insights from the SYMPHONY Phase 3 trial of AXS-12 (reboxetine) in narcolepsy patients. AXS-12 demonstrated significant reductions in cataplexy attacks, improved daytime wakefulness, and... 
Via Benzinga
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
From Axsome Therapeutics, Inc.
Via GlobeNewswire
What Analysts Are Saying About Axsome Therapeutics Stock
Via Benzinga
What Analysts Are Saying About Axsome Therapeutics Stock
Via Benzinga
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move
The price could be right for these three biopharma stocks. 
Via The Motley Fool
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Earnings Outlook For Axsome Therapeutics
Via Benzinga
The Latest Analyst Ratings For Axsome Therapeutics
Via Benzinga
The Analyst Landscape: 6 Takes On Axsome Therapeutics
Via Benzinga
Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
From Axsome Therapeutics, Inc.
Via GlobeNewswire
3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024
Find out which under-the-radar biotech stocks have major catalysts on the horizon, and unlock their explosive growth potential. 
Via InvestorPlace
3 Biotech Stocks to Buy and Hold for the Next 10 Years
There's a lot to like about these three drugmakers right now, and that shouldn't stop anytime soon. 
Via The Motley Fool
Axsome Therapeutics (AXSM) Q4 2023 Earnings Call Transcript
AXSM earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Neurology-Focused Axsome Therapeutics Reports Deeper Than Expected Q4 Loss, Updates Upcoming Pipeline Milestones
Axsome Therapeutics Q4 2023 revenues surge to $71.53 million, Auvelity sales hit $130.1 million for the year. Sunosi sees 67% YoY growth. 
Via Benzinga
Axsome Tumbles On An Unexpected Setback For Its Alzheimer's Drug
The company is testing a treatment for patients with agitation due to Alzheimer's disease. 
Via Investor's Business Daily
Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
2 Stocks That Could Double Your Money in 5 Years
These market-beating stocks could be just getting started. 
Via The Motley Fool
UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst
UBS bullish on Axsome's Auvelity launch and pipeline, foreseeing $1 billion sales by 2030. Buy rating, $111 price target. Positive Phase 3 data for Alzheimer's Agitation and Narcolepsy. 
Via Benzinga
5 medical stocks growing earnings by triple digits
There is a little known way to pick stocks like the pros do, and today's exercise points you to five high-probability winners in a sector that's quickly turning 
Via MarketBeat
Topics Economy
Exposures Economy
Earnings Scheduled For February 20, 2024
Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.36 per share on revenue of $7.38 billion. 
Via Benzinga
Cramer Praises Asset Manager's 'Amazing Quarter,' But As For SolarEdge? 'Too Hard To Own'
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended buying BlackRock, Inc. (NYSE: BLK). 
Via Benzinga
Axsome Depression Drug's Commercial Success, Pipeline Potential Undervalued, Analyst Says
Axsome Therapeutics' growth potential with RBC Capital's optimistic coverage. Auvelity's rapid Rx growth projects sales of $296M in 2024, outperforming estimates. 
Via Benzinga
Axsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating
Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
From Axsome Therapeutics, Inc.
Via GlobeNewswire
3 Stocks That Have Turned $50,000 Into More Than $500,000 in Just 5 Years
Is it too late to invest in these fast-growing stocks? 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanRafael.com & California Media Partners, LLC. All rights reserved.